Literature DB >> 24625335

Characteristics of the hypertensive patients with good and poor compliance to long-term salt restriction.

Minako Sakaki1, Takuya Tsuchihashi, Kimika Arakawa.   

Abstract

Although salt restriction is very important for the management of blood pressure (BP), it is difficult to maintain low salt intake in hypertensive patients. The purpose of the present study is to investigate comparatively the characteristics of hypertensive patients with good or poor compliance to long-term salt restriction. Subjects included 248 hypertensive patients who underwent successful 24-h home urine collection for >5 times with the observation period of 9.4 years in average. When the subjects were categorized based on the mean 24-h urinary salt excretion during the observation period to the groups with good (<8 g/day) or poor (10 g/day or more) compliance to long-term salt restriction, subjects with poor compliance were more frequently to be male, younger and had higher BMI than those with good compliance. Although there were no significant differences in BP and the number of antihypertensive drugs between the subjects with good and poor compliance, the subjects with poor compliance were given more diuretics, more frequently complicated with diabetes mellitus and hyperuricemia and had higher urinary protein excretion than those with good compliance. Thus, strict nutritional intervention and the management of BP as well as the complicated cardiovascular risk are important for the patients with poor compliance to salt restriction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24625335     DOI: 10.3109/10641963.2014.892119

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  1 in total

1.  Current prescription status of antihypertensive drugs with special reference to the use of diuretics in Japan.

Authors:  Ai Ibaraki; Wataru Goto; Rie Iura; Mitsuhiro Tominaga; Takuya Tsuchihashi
Journal:  Hypertens Res       Date:  2016-09-01       Impact factor: 3.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.